198 related articles for article (PubMed ID: 9305316)
1. Anticytokine antibodies in beta interferon-treated MS patients and the need for testing: plight of the practicing neurologist.
Pachner AR
Neurology; 1997 Sep; 49(3):647-50. PubMed ID: 9305316
[No Abstract] [Full Text] [Related]
2. Measurement of antibodies to interferon beta in patients with multiple sclerosis.
Pachner AR
Arch Neurol; 2001 Aug; 58(8):1299-300. PubMed ID: 11493174
[No Abstract] [Full Text] [Related]
3. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
4. Neutralising and binding anti-interferon-beta-I b (IFN-beta-I b) antibodies during IFN-beta-I b treatment of multiple sclerosis.
Kivisäkk P; Alm GV; Tian WZ; Matusevicius D; Fredrikson S; Link H
Mult Scler; 1997 Jun; 3(3):184-90. PubMed ID: 9310964
[TBL] [Abstract][Full Text] [Related]
5. The significance of neutralizing antibodies in patients with multiple sclerosis treated with interferon beta.
Rice G
Arch Neurol; 2001 Aug; 58(8):1297-8. PubMed ID: 11493173
[No Abstract] [Full Text] [Related]
6. [Formation of neutralizing antibodies in therapy of multiple sclerosis with interferon beta-1b. Practical procedure in suspected therapeutic failure].
Walther EU; Dang T; Hartung HP; Hohlfeld R
Nervenarzt; 1997 Dec; 68(12):935-9. PubMed ID: 9465334
[TBL] [Abstract][Full Text] [Related]
7. The evolution of neutralizing antibodies in multiple sclerosis patients treated with interferon beta-1b.
Rice GP; Paszner B; Oger J; Lesaux J; Paty D; Ebers G
Neurology; 1999 Apr; 52(6):1277-9. PubMed ID: 10214759
[TBL] [Abstract][Full Text] [Related]
8. Qualitative and quantitative analysis of antibody response against IFNbeta in patients with multiple sclerosis.
Gilli F; Hoffmann F; Sala A; Marnetto F; Caldano M; Valentino P; Kappos L; Bertolotto A; Lindberg RL
Mult Scler; 2006 Dec; 12(6):738-46. PubMed ID: 17263001
[TBL] [Abstract][Full Text] [Related]
9. Neutralizing antibodies (NABS) and interferon beta-1b therapy of multiple sclerosis.
Horowski R; Stürzebecher CS; Kapp JF
Funct Neurol; 2001; 16(2):117-28. PubMed ID: 11495417
[No Abstract] [Full Text] [Related]
10. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
[TBL] [Abstract][Full Text] [Related]
11. Commentary on neutralizing antibodies to interferon beta in patients with multiple sclerosis.
Whitaker JN
Arch Neurol; 2001 Aug; 58(8):1301. PubMed ID: 11493175
[No Abstract] [Full Text] [Related]
12. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
13. A comparative study of the relative bioavailability of different interferon beta preparations.
Deisenhammer F; Mayringer I; Harvey J; Dilitz E; Gasse T; Stadlbauer D; Reindl M; Berger T
Neurology; 2000 Jun; 54(11):2055-60. PubMed ID: 10851362
[TBL] [Abstract][Full Text] [Related]
14. Anticytokine antibodies in beta-interferon-treated patients.
Sibley W; Paty D; Rice GP; Masuoka LK
Neurology; 1998 Jun; 50(6):1930-2. PubMed ID: 9633778
[No Abstract] [Full Text] [Related]
15. Interferon beta neutralizing antibodies in multiple sclerosis: neutralizing activity and cross-reactivity with three different preparations.
Bertolotto A; Malucchi S; Milano E; Castello A; Capobianco M; Mutani R
Immunopharmacology; 2000 Jul; 48(2):95-100. PubMed ID: 10936507
[TBL] [Abstract][Full Text] [Related]
16. [The formation and significance of antibodies to interferon beta during immunomodulating treatment of multiple sclerosis].
Bartosik-Psujek H; Stelmasiak Z
Neurol Neurochir Pol; 2004; 38(1 Suppl 1):S53-6. PubMed ID: 15045868
[TBL] [Abstract][Full Text] [Related]
17. [Beta-interferon neutralizing antibodies. Do they have clinical value in patients with multiple sclerosis?].
Romero López J; Maciñeiras Montero JL
Med Clin (Barc); 2005 Feb; 124(4):144-5. PubMed ID: 15713245
[No Abstract] [Full Text] [Related]
18. Immunogenicity of an interferon-beta1a product.
Kauffman MA; Sterin-Prync A; Papouchado M; González E; Vidal AJ; Grossberg SE; Chuppa S; Odoriz B; Vrech C; Diez RA; Ferro HH
Int J Immunopathol Pharmacol; 2011; 24(2):499-504. PubMed ID: 21658324
[TBL] [Abstract][Full Text] [Related]
19. [Immunotherapy of multiple sclerosis. Consensus and controversies].
Hohlfeld R
Nervenarzt; 1999 Apr; 70(4):297. PubMed ID: 10354989
[No Abstract] [Full Text] [Related]
20. Anti-interferon-beta neutralising activity is not entirely mediated by antibodies.
Gilli F; Marnetto F; Caldano M; Valentino P; Granieri L; Di Sapio A; Capobianco M; Sala A; Malucchi S; Kappos L; Lindberg RL; Bertolotto A
J Neuroimmunol; 2007 Dec; 192(1-2):198-205. PubMed ID: 17950468
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
